Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Joon Seong Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8048-9990; OpenAlex author ID A5100715667, A5122838644. Sources: OpenAlex.

Their work

Papers
42 (first author 4, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
84
Papers, trials and grants by year

2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 5 papers · 2022: 7 papers · 2023: 6 papers · 2024: 5 papers · 2025: 6 papers · 2026: 4 papers

Papers 42

  1. Estrogen receptor expression as a predictive biomarker for patient-derived xenograft engraftment in pancreatic cancer: A pilot study. First author DOI 10.1016/j.pan.2026.10.009↗
  2. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Co-author DOI 10.1016/j.suronc.2026.102368↗
  3. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Co-author DOI 10.1245/s10434-025-18349-8↗
  4. Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matchi… Co-author DOI 10.4174/astr.2026.111.2.93↗
  5. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-11833-y↗
  6. The FOXP1-ABCG2 axis promotes the proliferation of cancer stem cells and induces chemoresistance in pancreatic cancer. Last author DOI 10.1038/s41417-025-00896-7↗
  7. SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells. Last author DOI 10.1038/s41419-025-07476-5↗
  8. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… Co-author DOI 10.1245/s10434-024-16743-2↗
  9. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Co-author DOI 10.1245/s10434-025-18123-w↗
  10. Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic duc… Co-author DOI 10.4174/astr.2025.109.2.61↗
  11. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. Co-author DOI 10.1002/jhbp.12048↗
  12. Emerging role of local treatment in the era of advanced systemic treatment in pancreatic cancer with liver metastasis: A systematic review and meta-analysis. Co-author DOI 10.1002/jhbp.12051↗
  13. Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-024-02676-w↗
  14. Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2. Last author DOI 10.32604/or.2024.044029↗
  15. Novel Predictive Strategy Using CA19-9 and Fecal Elastase Levels to Make Treatment Decisions for Resectable Pancreatic Cancer: A Retrospective Study. Last author DOI 10.3390/biomedicines13010062↗
  16. The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC. Last author DOI 10.1007/s00109-023-02369-6↗
  17. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin … Last author DOI 10.1080/15384047.2023.2272334↗
  18. Effective Circulating Tumor Cell Isolation Using Epithelial and Mesenchymal Markers in Prostate and Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers15102825↗
  19. Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining. Co-author DOI 10.3390/cancers15225413↗
  20. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer. Last author DOI 10.3390/cells12202509↗
  21. CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer. Last author DOI 10.3390/ijms241612993↗
  22. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  23. Identification of circulating myeloid cells as a potential diagnosis and recurrence marker of pancreatic ductal adenocarcinoma through the single-cell analysis Co-author DOI 10.21203/rs.3.rs-2345667/v1↗
  24. Intraoperative Radiotherapy for Resectable Pancreatic Cancer Using a Low-Energy X-Ray Source: Postoperative Complications and Early Outcomes. Co-author DOI 10.3349/ymj.2022.63.5.405↗
  25. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Last author DOI 10.3389/fphar.2022.934746↗
  26. Validation of IL-7R as an Immunological Biomarker for Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14030853↗
  27. Modeling Pancreatic Cancer with Patient-Derived Organoids Integrating Cancer-Associated Fibroblasts. Co-author DOI 10.3390/cancers14092077↗
  28. The role of Jagged1 as a dynamic switch of cancer cell plasticity in PDAC assembloids. Co-author DOI 10.7150/thno.71364↗
  29. Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, r… Co-author DOI 10.1007/s00595-021-02280-y↗
  30. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells. Co-author DOI 10.1016/j.canlet.2020.10.012↗
  31. Immune-modulating Effect of Korean Red Ginseng by Balancing the Ratio of Peripheral T Lymphocytes in Bile Duct or Pancreatic Cancer Patients With Adjuvant Chem… Co-author DOI 10.21873/invivo.12454↗
  32. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.3390/jcm10040873↗
  33. Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Resul… Co-author DOI 10.5009/gnl20306↗
  34. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-42501-6↗
  35. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer. Last author DOI 10.1038/s41598-019-53831-w↗
  36. A phase II study of intraoperative radiotherapy using a low-energy x-ray source for resectable pancreatic cancer: a study protocol. Co-author DOI 10.1186/s12893-019-0492-x↗
  37. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospect… Co-author DOI 10.1097/sla.0000000000002705↗
  38. Preoperative fecal elastase-1 is a useful prognostic marker following curative resection of pancreatic cancer. First author DOI 10.1016/j.hpb.2016.12.007↗
  39. Surgical management of malignant bowel obstruction in recurrent pancreatic cancer. First author DOI 10.1016/j.ijscr.2017.01.021↗
  40. ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.355↗
  41. Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2015.400↗
  42. A Study on the Dietary Intake and the Nutritional Status among the Pancreatic Cancer Surgical Patients. First author DOI 10.7762/cnr.2016.5.4.279↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 14 shared papers, 2018–2026 · strength 3.14
  2. Hye‐Sol Jung · 12 shared papers, 2024–2026 · strength 2.99
  3. Jin‐Young Jang · 13 shared papers, 2018–2026 · strength 2.78
  4. Won‐Gun Yun · 9 shared papers, 2024–2026 · strength 2.23
  5. Hyung Sun Kim · 13 shared papers, 2017–2024 · strength 2.08
  6. Yoon Soo Chae · 8 shared papers, 2024–2026 · strength 2.03
  7. Hyeon Woong Kang · 8 shared papers, 2022–2025 · strength 1.56
  8. Go‐Won Choi · 5 shared papers, 2025–2026 · strength 1.31
  9. Younsoo Seo · 5 shared papers, 2025–2026 · strength 1.31
  10. Woosol Chris Hong · 6 shared papers, 2022–2025 · strength 1.16
  11. Sung Ill Jang · 6 shared papers, 2021–2024 · strength 0.95
  12. Dong Sup Yoon · 9 shared papers, 2016–2021 · strength 0.87
  13. Myeong‐Jin Kim · 5 shared papers, 2022–2023 · strength 0.85
  14. Da Eun Lee · 4 shared papers, 2022–2024 · strength 0.73
  15. Dong Ki Lee · 5 shared papers, 2016–2024 · strength 0.69
  16. Joohee Jung · 1 shared paper, 2026 · strength 0.50
  17. Hyun-Kyung Lim · 1 shared paper, 2026 · strength 0.50
  18. Jae Hee Cho · 3 shared papers, 2022–2023 · strength 0.49
  19. Jin‐Young Jang · 2 shared papers, 2025 · strength 0.48
  20. Youngmin Han · 2 shared papers, 2025 · strength 0.48
  21. Minsoo Kim · 2 shared papers, 2025 · strength 0.48
  22. Hyung Keun Lee · 3 shared papers, 2022–2024 · strength 0.46
  23. Yun Sun Lee · 3 shared papers, 2019–2023 · strength 0.45
  24. Mirang Lee · 2 shared papers, 2024 · strength 0.43
  25. Ik Jae Lee · 3 shared papers, 2018–2022 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.